The Wuhan SARS-CoV-2—What's next for China

Hongzou Lu1 | Charles W. Stratton2 | Yi-Wei Tang3

1Department of Infectious Diseases, Shanghai Public Health Clinical Center, Fudan University, Shanghai, China
2Department of Pathology, Microbiology and Immunology, Vanderbilt University Medical Center, Nashville, Tennessee
3Cepheid, Danaher Diagnostic Platform, Shanghai, China

When an outbreak of pneumonia of unknown etiology occurred in Wuhan City, Hubei Province, China, in December 2019, the mystery1 was the nature of the causative agent. As many of the patients had visited a fish and wild animal market, the possibility of a recurrence of severe acute respiratory syndrome (SARS) needed to be investigated.2 Finally, could this outbreak of pneumonia be caused by a novel coronavirus that was different from those causing SARS or Middle East respiratory syndrome (MERS)? Once this outbreak was recognized as a serious threat, a special team consisting of physicians, scientists, and epidemiologists began to investigate these possibilities. Within 9 days, SARS and MERS had been ruled out and a novel coronavirus had been isolated in Wuhan; this coronavirus is now officially named as the SARS-CoV-2 by the International Committee on Taxonomy of Viruses. The breadth and nature of the investigation that identified this novel SARS-CoV-2 is elaborately described by Zhu and colleagues in a recent publication in The New England Journal of Medicine.4 Additional details subsequently have been published in several prestigious journals.5‑14 This study is quite remarkable and praiseworthy.

Given the subsequent spread to other parts of China as well as to other countries, the reasons for this spread should be examined. There are two such reasons that are noteworthy. The first is that the potential threat of these initial cases of pneumonia was not well-appreciated. The second reason is simply the timing of this outbreak; the outbreak began just before the Chinese New Year. By the time the investigation had been completed, the Chinese New Year was underway. The Chinese New Year is one of the most important holidays in China and celebrates the beginning of the new year on the traditional Chinese calendar. The first day of the Chinese New Year was on 25 January 2020. The Chinese New Year is associated with a number of customs; among these is returning home for an annual reunion dinner. Thus, traveling home had already begun by the time Chinese authorities attempted to curtail the spread of the coronavirus by extending the lunar new year holidays and suspending travel.14 This made control measure of the outbreak more difficult. The net effect of the initial delay in the investigation and the holiday travel was, in effect, the “Perfect Storm.”

The results of the spread within China of the SARS-CoV-2 are considerable and still unfolding. Given the timing of this outbreak, the inability of the Chinese government’s measures to control this epidemic and limit most of these cases to Wuhan is understandable. The question then is, “What’s next for China?” As earlier suggested, there remains considerable work to be done.1 This study includes many issues that can be determined in the short term as well as some that will require long-term solutions. Some of these issues are as follows. The timing of colonization, infection, and shedding need to be determined. For example, are infected persons first colonized? Do infected persons shed virus before they have clinical symptoms? Transmission characteristics need to be determined. Is infectious transmission limited to respiratory droplets or can the virus be transmitted by contact with an infected person? Efficient human-to-human transmission is required for large-scale spread (ie, an epidemic or pandemic) of any emerging virus. Therefore, the basic reproductive ratio during this epidemic needs to be determined; the basic reproductive ratio is defined as the average number of secondary cases that an infected person produces during their entire infectious period in a susceptible and uninfected population.15 The case-fatality rate needs to be accurately determined; the case-fatality rate of the SARS-CoV was around 11%. Some of these questions are already being addressed,16,17 but further work is needed. Often serology is required in such an epidemic to determine how many persons may have had clinically inapparent infections. Detection and identification methods that are accurate and can be performed in real time at the point of care or in the field need to be developed.1 The exact relationship between the SARS-CoV-2 and animals (eg, bats)
needs to be determined. \(^4\,18\,19\) Although bats are suspected, the question of how the virus has moved from bats to the human host needs to be resolved. Does this transmission involve intermediate animal hosts as occurred with SARS-CoV and MERS-CoV? If the SARS-CoV-2 proves to have an animal sources, the continued presence of live animal markets in China must be seriously questioned. In the long term, the development of vaccines and antiviral therapy needs to be a higher priority than it has been since the SARS pandemic in 2002 to 2003; the lack of a SARS vaccine or SARS antiviral therapy suggests that such research has not been a priority. For example, Ampligen (poly I:poly C124) has been shown to inhibit SARS-CoV in a murine lung model, yet has not been further evaluated in humans. \(^20\) Similarly, Remdesivir (GS-5734) has been shown to inhibit both epidemic and zoonotic coronaviruses. \(^21\) It is likely that continued investigation of new antiviral agents with activity against coronaviruses in the absence of ongoing active epidemics would be enhanced by government incentives. Another issue in the long term that needs to be addressed is the potential of novel coronaviruses to spread within medical centers to health care workers as has happened with SARS-CoV and MERS-CoV.\(^22\,\,24\) Most medical centers, whether in China or in the United States, are not prepared for such a problem. For example, negative-pressure containment rooms with proper anterooms are either not found or found only in limited numbers in medical centers in the United States.\(^25\)

The recent epidemic in China caused by the SARS-CoV-2 is yet another example of emerging zoonotic viral diseases.\(^18\) Like previous epidemics/pandemics caused by novel members of the coronavirus family, there are many lessons to be learned. Much work remains to be done before this latest coronavirus is fully understood and these lessons can be learned.

**AUTHOR CONTRIBUTIONS**

Concept forming: HL and Y-WT. Writing: CWS. Revising and editing: HL and Y-WT.

**ORCID**

 Yi-Wei Tang https://orcid.org/0000-0003-4888-6771

**REFERENCES**

1. Lu H, Stratton CW, Tang YW. Outbreak of pneumonia of unknown etiology in Wuhan China: the mystery and the miracle. J Med Virol. 2020;92(4):401-402.

2. de Wit E, van Doremalen N, Falzarano D, Munster VJ. SARS and MERS: recent insights into emerging coronaviruses. Nat Rev Microbiol. 2016;14(8):523-534. https://doi.org/10.1038/nrmicro.2016.1081

3. Cui J, Li F, Shi ZL. Origin and evolution of pathogenic coronaviruses. Nat Rev Microbiol. 2019;17(3):181-192. https://doi.org/10.1038/s41579-018-0118-4

4. Zhu N, Zhang D, Wang W, et al. A novel coronavirus from patients with pneumonia in China, 2019. N Engl J Med. 2020;382(8):727-733.

5. Li Q, Guan X, Wu P, et al. Early transmission dynamics in Wuhan, China, of novel coronavirus-infected pneumonia. N Engl J Med. 2020.

6. Chen L, Liu W, Zhang Q, et al. RNA based mNGS approach identifies a novel human coronavirus from two individual pneumonia cases in 2019 Wuhan outbreak. Emerg Microbes Infect. 2020;9(1):313-319. https://doi.org/10.1080/22221751.2222020.21725399

7. Chan JF, Kok KH, Zhu Z, et al. Genomic characterization of the 2019 novel human-pathogenic coronavirus isolated from a patient with atypical pneumonia after visiting Wuhan. Emerg Microbes Infect. 2020;9(1):221-236. https://doi.org/10.1080/22221751.2222020.21719902

8. Holshue ML, DeBolt C, Lindquist S, et al. First case of 2019 novel coronavirus in the United States. N Engl J Med. 2020.

9. Huang C, Wang Y, Li X, et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet. 2020;395:497-506.

10. Lu R, Zhao X, Li J, et al. Genomic characterisation and epidemiology of 2019 novel coronavirus: implications for virus origins and receptor binding. Lancet. 2020;395:556-574.

11. Rothe C, Schunk M, Sothmann P, et al. Transmission of 2019-nCoV infection from an asymptomatic contact in Germany. N Engl J Med. 2020.

12. Wang D, Hu B, Hu C, et al. Clinical characteristics of 138 hospitalized patients with 2019 novel coronavirus-infected pneumonia in Wuhan, China. JAMA. 2020.

13. Zhou P, Yang XL, Wang XG, et al. A pneumonia outbreak associated with a new coronavirus of probable bat origin. Nature. 2020.

14. Kofi Ayittey F, Dzuvor C, Kormla Ayittey M, Bennita Chiwero N, Habib A. Updates on Wuhan 2019 novel coronavirus epidemic. J Med Virol. 2020;92(4):403-407.

15. Heffernan JM, Smith RJ, Wahl LM. Perspectives on the basic reproductive ratio. J R Soc Interface. 2005;2(4):281-293. https://doi.org/10.1098/rsif.2005.0042

16. Xu Z, Li S, Tian S, Li H, Kong L. Full spectrum of COVID-19 severity still being depicted. Lancet. 2020. https://doi.org/10.1016/s0140-6736(20)30208-1

17. Park SW, Bolker BM, Champredon D, et al. Reconciling early-outbreak estimates of the basic reproduction number and its uncertainty, a new framework and applications to the novel coronavirus (2019-NCoV) outbreak. medRxiv. 2020. https://doi.org/10.1101/2020.01.30.20019877

18. Liu P, Chen W, Chen JP. Viral metagenomics revealed sendai virus and coronavirus infection of Malayan pangolins (Manis javanica). Viruses. 2019;11(11):979. https://doi.org/10.1128/MMI.22222020.21725399

19. Wang LF, Cramer G. Emerging zoonotic viral diseases. Rev Sci Tech. 2014;33(2):569-581. https://doi.org/10.20506/rst.2014.33.2.365

20. Barnard DL, Day CW, Bailey K, et al. Evaluation of immunomodulators, interferons and known in vitro SARS-CoV inhibitors for inhibition of SARS-CoV replication in BALB/c mice. Antivir Chem Chemother. 2006;17(5):275-284. https://doi.org/10.1177/095567340601700505

21. Sheahan TP, Sims AC, Graham RL, et al. Broad-spectrum antiviral GS-5734 inhibits both epidemic and zoonotic coronaviruses. Sci Transl Med. 2017;9:eaax1365.

22. Assiri A, McGeer A, Perl TM, et al. Hospital outbreak of Middle East respiratory syndrome coronavirus. N Engl J Med. 2013;369(5):407-416. https://doi.org/10.1056/NEJMoia1306742

23. McDonald LC, Simor AE, Su J, et al. SARS in healthcare facilities, Toronto and Taiwan. Emerg Infect Dis. 2004;10(5):777-781. https://doi.org/10.3201/eid1005.030791

24. Munster VJ, Koopmans M, van Doremalen N, van Riel D, de Wit E. A novel coronavirus emerging in China—key questions for impact assessment. N Engl J Med. 2020;382:692-694.

25. Smith PW, Anderson AO, Christopher GW, et al. Designing a biocontainment unit to care for patients with serious communicable diseases: a consensus statement. Biosec Bioterr. 2006;4:351-365.

**How to cite this article:** Lu H, Stratton CW, Tang Y-W. The Wuhan SARS-CoV-2—What's next for China. J Med Virol. 2020;92:546-547. https://doi.org/10.1002/jmv.25738